Add Yahoo as a preferred source to see more of our stories on Google. President Donald Trump’s approach to lowering drug prices has leaned heavily on executive orders and voluntary deals with ...

The U.S. Centers for Medicare & Medicaid Services (CMS) announced the selection of 15 high-cost prescription drugs for the third cycle of the Medicare Drug Price Negotiation Program, marking the first ...

On May 12, 2025, the Centers for Medicare & Medicaid Services (CMS) issued draft guidance for the third cycle of the IRA’s Medicare Drug Price Negotiation Program (Negotiation Program). This draft ...

As President Donald Trump touts new deals to cut the cost of blockbuster drugs like Wegovy and Zepbound, he’s barely mentioned Medicare’s drug price negotiation program — even though the government is ...

Hello and welcome to Health Affairs This Week. I'm your host, Jeff Byers. We are recording on 11/04/2025. In late September, CMS published its final guidance for the third cycle of the Medicare drug ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. WASHINGTON — The Trump administration is ...

As President Donald Trump touts new deals to cut the cost of blockbuster drugs like Wegovy and Zepbound, he’s barely mentioned Medicare’s drug price negotiation program — even though the government is ...

This article is the latest in the Health Affairs Forefront featured topic, “Health Policy at a Crossroads,” produced with the support of the Commonwealth Fund and the Robert Wood Johnson Foundation.

“While we support affordable health care, the price controls that we are challenging would reduce access to new medicines that Americans are counting on, and would set a devastating precedent for all ...

On September 30, 2025, the Centers for Medicare & Medicaid Services (CMS) issued final guidance (Final Guidance) for initial price applicability year (IPAY) 2028 of the Inflation Reduction Act (IRA) ...

The One Big Beautiful Bill Act removed a number of orphan drugs from being subject to price negotiations, and this could cost the Medicare program $8.8 billion over the course of about 10 years. That ...